Table 2.
Primary, sub-group, secondary, and sensitivity outcome data for included trials
| Outcome | References | Intervention group | Control group | Conventional effect estimate (95% CI) |
Overall effect | I2 (%) |
|---|---|---|---|---|---|---|
| Overall mortality | [19–21, 23–28] | 821/3358 (24.4%) | 909/3135 (29%) | 0.87 (0.74–1.01) | Z = 1.82 p = 0.07 | 10 |
| ICU patient mortality | [19, 21, 23] | 254/732 (34.7%) | 297/750 (39.6%) | 0.84 (0.65–1.10) | Z = 1.27 p = 0.20 | 24 |
| Disease progression | ||||||
| Mechanical ventilation | [20, 21, 23–26, 28] | 152/1742 (8.7%) | 152/1454 (10.5%) | 0.70 (0.54–0.89) | Z = 2.86 p = 0.004 | 0 |
| ICU admission | [20, 23, 26, 28] | 118/338 (34.9%) | 117/282 (41.5%) | 0.73 (0.38–1.39) | Z = 0.96 p = 0.34 | 60 |
| Composite outcome | [18–21, 23–27] | 808/2796 (28.9%) | 943/2577 (36.6%) | 0.72 (0.59–0.89) | Z = 3.14 p = 0.002 | 26 |
| Sensitivity analysis | ||||||
| Combined IL-6 antagonists mortality | [19–28] | 861/3738 (23%) | 916/3219 (28.5%) | 0.86 (0.74–1.01) | Z = 1.85 p = 0.06 | 10 |
| Sarilumab mortality | [19, 23] | 40/377 (10.6%) | 149/481 (31%) | 0.72 (0.35–1.51) | Z = 0.86 p = 0.39 | 42 |
ICU intensive-care unit